Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Size was estimated at USD 7790.46 million in 2022 and is projected to reach USD 18825.17 million by 2028, exhibiting a CAGR of 13.43% during the forecast period.
Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Overview:
Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Report 2022 comes with the extensive industry analysis with development components, patterns, flows and sizes. The report also calculates present and past market values to forecast potential market management through the forecast period between 2022-2028.This research study of Glucagon Like Peptide-1 (GLP-1) Agonists involved the extensive usage of both primary and secondary data sources. This includes the study of various parameters affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry.
Scope of the Glucagon Like Peptide-1 (GLP-1) Agonists Market
The Glucagon Like Peptide-1 (GLP-1) Agonists Market Research report incorporate value chain analysis for each of the product type. Value chain analysis offers in depth information about value addition at each stage.The study includes drivers and restraints for Glucagon Like Peptide-1 (GLP-1) Agonists Market along with their impact on demand during the forecast period. The study also provides key market indicators affecting thegrowth of the market. Research report includes major key player analysis with shares of each player inside market, growth rate and market attractiveness in different endusers/regions. Our study Glucagon Like Peptide-1 (GLP-1) Agonists Market helps user to make precise decision in order to expand their market presence and increase market share.
Impact of COVID-19 on Glucagon Like Peptide-1 (GLP-1) Agonists Market
Report covers Impact of Coronavirus COVID-19: Since the COVID-19 virus outbreak in December 2019, the disease has spread to almost every country around the globe with the World Health Organization declaring it a public health emergency. The global impacts of the coronavirus disease 2019 (COVID-19) are already starting to be felt, and will significantly affect the Glucagon Like Peptide-1 (GLP-1) Agonists market in 2020. The outbreak of COVID-19 has brought effects on many aspects, like flight cancellations; travel bans and quarantines; restaurants closed; all indoor/outdoor events restricted; over forty countries state of emergency declared; massive slowing of the supply chain; stock market volatility; falling business confidence, growing panic among the population, and uncertainty about future.
Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Segmentation
Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Research report comprises of Porter's five forces analysis to do the detail study about its each segmentation like Product segmentation, End user/application segment analysis and Major key players analysis mentioned as below;
By Type, Glucagon Like Peptide-1 (GLP-1) Agonists market has been segmented into:
Exenatied
Liraglutide
Lixisenatide
Albiglutide
Dulaglutide
By Application, Glucagon Like Peptide-1 (GLP-1) Agonists market has been segmented into:
Hospital
Pharmacy
Other
Regional Analysis:
North America (U.S., Canada, Mexico)
Europe (Germany, U.K., France, Italy, Russia, Spain, Rest of Europe)
Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of APAC)
South America (Brazil, Argentina, Rest of SA)
Middle East & Africa (Turkey, Saudi Arabia, Iran, UAE, Africa, Rest of MEA)
Competitive Landscape:
Competitive analysis is the study of strength and weakness, market investment, market share, market sales volume, market trends of major players in the market.The Glucagon Like Peptide-1 (GLP-1) Agonists market study focused on including all the primary level, secondary level and tertiary level competitors in the report. The data generated by conducting the primary and secondary research.The report covers detail analysis of driver, constraints and scope for new players entering the Glucagon Like Peptide-1 (GLP-1) Agonists market.
Top Key Players Covered in Glucagon Like Peptide-1 (GLP-1) Agonists market are:
Novo Nordisk
AstraZeneca
Eli Lily
GSK
Sanofi
Bristol-Myers Squibb
Amylin
Objective to buy this Report:
1. Glucagon Like Peptide-1 (GLP-1) Agonists analysis predicts the representation of this market, supply and demand, capacity, detailed investigations, etc.
2. Even the report, along with the international series, conducts an in-depth study of rules, policies and current policy.
3. In addition, additional factors are mentioned: imports, arrangement of commodity prices for the market, supply and demand of industry products, major manufacturers.
4. The report starts with Glucagon Like Peptide-1 (GLP-1) Agonists market statistics and moves to important points, with dependent markets categorized by market trend by application.
5. Applications of market may also be assessed based on their performances.
6. Other market attributes, such as future aspects, limitations and growth for all departments.
Chapter 1: Introduction
1.1 Research Objectives
1.2 Research Methodology
1.3 Research Process
1.4 Scope and Coverage
1.4.1 Market Definition
1.4.2 Key Questions Answered
1.5 Market Segmentation
Chapter 2:Executive Summary
Chapter 3:Growth Opportunities By Segment
3.1 By Type
3.2 By Application
Chapter 4: Market Landscape
4.1 Porter's Five Forces Analysis
4.1.1 Bargaining Power of Supplier
4.1.2 Threat of New Entrants
4.1.3 Threat of Substitutes
4.1.4 Competitive Rivalry
4.1.5 Bargaining Power Among Buyers
4.2 Industry Value Chain Analysis
4.3 Market Dynamics
4.3.1 Drivers
4.3.2 Restraints
4.3.3 Opportunities
4.5.4 Challenges
4.4 Pestle Analysis
4.5 Technological Roadmap
4.6 Regulatory Landscape
4.7 SWOT Analysis
4.8 Price Trend Analysis
4.9 Patent Analysis
4.10 Analysis of the Impact of Covid-19
4.10.1 Impact on the Overall Market
4.10.2 Impact on the Supply Chain
4.10.3 Impact on the Key Manufacturers
4.10.4 Impact on the Pricing
Chapter 5: Glucagon Like Peptide-1 (GLP-1) Agonists Market by Type
5.1 Glucagon Like Peptide-1 (GLP-1) Agonists Market Overview Snapshot and Growth Engine
5.2 Glucagon Like Peptide-1 (GLP-1) Agonists Market Overview
5.3 Exenatied
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size (2016-2028F)
5.3.3 Key Market Trends, Growth Factors and Opportunities
5.3.4 Exenatied: Geographic Segmentation
5.4 Liraglutide
5.4.1 Introduction and Market Overview
5.4.2 Historic and Forecasted Market Size (2016-2028F)
5.4.3 Key Market Trends, Growth Factors and Opportunities
5.4.4 Liraglutide: Geographic Segmentation
5.5 Lixisenatide
5.5.1 Introduction and Market Overview
5.5.2 Historic and Forecasted Market Size (2016-2028F)
5.5.3 Key Market Trends, Growth Factors and Opportunities
5.5.4 Lixisenatide: Geographic Segmentation
5.6 Albiglutide
5.6.1 Introduction and Market Overview
5.6.2 Historic and Forecasted Market Size (2016-2028F)
5.6.3 Key Market Trends, Growth Factors and Opportunities
5.6.4 Albiglutide: Geographic Segmentation
5.7 Dulaglutide
5.7.1 Introduction and Market Overview
5.7.2 Historic and Forecasted Market Size (2016-2028F)
5.7.3 Key Market Trends, Growth Factors and Opportunities
5.7.4 Dulaglutide: Geographic Segmentation
Chapter 6: Glucagon Like Peptide-1 (GLP-1) Agonists Market by Application
6.1 Glucagon Like Peptide-1 (GLP-1) Agonists Market Overview Snapshot and Growth Engine
6.2 Glucagon Like Peptide-1 (GLP-1) Agonists Market Overview
6.3 Hospital
6.3.1 Introduction and Market Overview
6.3.2 Historic and Forecasted Market Size (2016-2028F)
6.3.3 Key Market Trends, Growth Factors and Opportunities
6.3.4 Hospital: Geographic Segmentation
6.4 Pharmacy
6.4.1 Introduction and Market Overview
6.4.2 Historic and Forecasted Market Size (2016-2028F)
6.4.3 Key Market Trends, Growth Factors and Opportunities
6.4.4 Pharmacy: Geographic Segmentation
6.5 Other
6.5.1 Introduction and Market Overview
6.5.2 Historic and Forecasted Market Size (2016-2028F)
6.5.3 Key Market Trends, Growth Factors and Opportunities
6.5.4 Other: Geographic Segmentation
Chapter 7: Company Profiles and Competitive Analysis
7.1 Competitive Landscape
7.1.1 Competitive Positioning
7.1.2 Glucagon Like Peptide-1 (GLP-1) Agonists Sales and Market Share By Players
7.1.3 Industry BCG Matrix
7.1.4 Heat Map Analysis
7.1.5 Glucagon Like Peptide-1 (GLP-1) Agonists Industry Concentration Ratio (CR5 and HHI)
7.1.6 Top 5 Glucagon Like Peptide-1 (GLP-1) Agonists Players Market Share
7.1.7 Mergers and Acquisitions
7.1.8 Business Strategies By Top Players
7.2 NOVO NORDISK
7.2.1 Company Overview
7.2.2 Key Executives
7.2.3 Company Snapshot
7.2.4 Operating Business Segments
7.2.5 Product Portfolio
7.2.6 Business Performance
7.2.7 Key Strategic Moves and Recent Developments
7.2.8 SWOT Analysis
7.3 ASTRAZENECA
7.4 ELI LILY
7.5 GSK
7.6 SANOFI
7.7 BRISTOL-MYERS SQUIBB
7.8 AMYLIN
Chapter 8: Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Analysis, Insights and Forecast, 2016-2028
8.1 Market Overview
8.2 Historic and Forecasted Market Size By Type
8.2.1 Exenatied
8.2.2 Liraglutide
8.2.3 Lixisenatide
8.2.4 Albiglutide
8.2.5 Dulaglutide
8.3 Historic and Forecasted Market Size By Application
8.3.1 Hospital
8.3.2 Pharmacy
8.3.3 Other
Chapter 9: North America Glucagon Like Peptide-1 (GLP-1) Agonists Market Analysis, Insights and Forecast, 2016-2028
9.1 Key Market Trends, Growth Factors and Opportunities
9.2 Impact of Covid-19
9.3 Key Players
9.4 Key Market Trends, Growth Factors and Opportunities
9.4 Historic and Forecasted Market Size By Type
9.4.1 Exenatied
9.4.2 Liraglutide
9.4.3 Lixisenatide
9.4.4 Albiglutide
9.4.5 Dulaglutide
9.5 Historic and Forecasted Market Size By Application
9.5.1 Hospital
9.5.2 Pharmacy
9.5.3 Other
9.6 Historic and Forecast Market Size by Country
9.6.1 U.S.
9.6.2 Canada
9.6.3 Mexico
Chapter 10: Europe Glucagon Like Peptide-1 (GLP-1) Agonists Market Analysis, Insights and Forecast, 2016-2028
10.1 Key Market Trends, Growth Factors and Opportunities
10.2 Impact of Covid-19
10.3 Key Players
10.4 Key Market Trends, Growth Factors and Opportunities
10.4 Historic and Forecasted Market Size By Type
10.4.1 Exenatied
10.4.2 Liraglutide
10.4.3 Lixisenatide
10.4.4 Albiglutide
10.4.5 Dulaglutide
10.5 Historic and Forecasted Market Size By Application
10.5.1 Hospital
10.5.2 Pharmacy
10.5.3 Other
10.6 Historic and Forecast Market Size by Country
10.6.1 Germany
10.6.2 U.K.
10.6.3 France
10.6.4 Italy
10.6.5 Russia
10.6.6 Spain
10.6.7 Rest of Europe
Chapter 11: Asia-Pacific Glucagon Like Peptide-1 (GLP-1) Agonists Market Analysis, Insights and Forecast, 2016-2028
11.1 Key Market Trends, Growth Factors and Opportunities
11.2 Impact of Covid-19
11.3 Key Players
11.4 Key Market Trends, Growth Factors and Opportunities
11.4 Historic and Forecasted Market Size By Type
11.4.1 Exenatied
11.4.2 Liraglutide
11.4.3 Lixisenatide
11.4.4 Albiglutide
11.4.5 Dulaglutide
11.5 Historic and Forecasted Market Size By Application
11.5.1 Hospital
11.5.2 Pharmacy
11.5.3 Other
11.6 Historic and Forecast Market Size by Country
11.6.1 China
11.6.2 India
11.6.3 Japan
11.6.4 Singapore
11.6.5 Australia
11.6.6 New Zealand
11.6.7 Rest of APAC
Chapter 12: Middle East & Africa Glucagon Like Peptide-1 (GLP-1) Agonists Market Analysis, Insights and Forecast, 2016-2028
12.1 Key Market Trends, Growth Factors and Opportunities
12.2 Impact of Covid-19
12.3 Key Players
12.4 Key Market Trends, Growth Factors and Opportunities
12.4 Historic and Forecasted Market Size By Type
12.4.1 Exenatied
12.4.2 Liraglutide
12.4.3 Lixisenatide
12.4.4 Albiglutide
12.4.5 Dulaglutide
12.5 Historic and Forecasted Market Size By Application
12.5.1 Hospital
12.5.2 Pharmacy
12.5.3 Other
12.6 Historic and Forecast Market Size by Country
12.6.1 Turkey
12.6.2 Saudi Arabia
12.6.3 Iran
12.6.4 UAE
12.6.5 Africa
12.6.6 Rest of MEA
Chapter 13: South America Glucagon Like Peptide-1 (GLP-1) Agonists Market Analysis, Insights and Forecast, 2016-2028
13.1 Key Market Trends, Growth Factors and Opportunities
13.2 Impact of Covid-19
13.3 Key Players
13.4 Key Market Trends, Growth Factors and Opportunities
13.4 Historic and Forecasted Market Size By Type
13.4.1 Exenatied
13.4.2 Liraglutide
13.4.3 Lixisenatide
13.4.4 Albiglutide
13.4.5 Dulaglutide
13.5 Historic and Forecasted Market Size By Application
13.5.1 Hospital
13.5.2 Pharmacy
13.5.3 Other
13.6 Historic and Forecast Market Size by Country
13.6.1 Brazil
13.6.2 Argentina
13.6.3 Rest of SA
Chapter 14 Investment Analysis
Chapter 15 Analyst Viewpoint and Conclusion
Publisher: Introspective Market Research
Related Reports
- Biosimilars Market based on by Material Type (Silicon, Germanium, Transition Metal Oxides, Gold), Industry (Consumer Electronics, Automotive, Aviation, Energy, Medical Devices), Regional Outlook- Global Forecast up to 2032
- Vaccines Market by Type (Recombinant/Conjugate/Subunit, Inactivated, Live Attenuated and Toxoid), Route of Administration (Parenteral and Oral), Disease Indication and Geography - Global Industry Analysis, Opportunities and Forecast up to 2030
- Heart Failure Market by Type (Chronic Heart Failure, Acute Heart Failure), Therapeutic Drug, Distribution Channel, End User, and Geography - Global Industry Analysis, Opportunities and Forecast up to 2030
- Rosacea Treatment Market by Type (Erythematotelangiectatic Rosacea, Ocular Rosacea, Papulopustular Rosacea, Phymatous Rosacea), Drug Class, Mode of Administration, Distribution Channel, and Geography - Global Industry Analysis, Opportunities and Forecast up to 2030
- Wearable Medical Devices Market by Product (Therapeutic Devices, Diagnostic Devices), Site (Handheld, Shoe Sensors, Headband, Strap/Clip/Bracelet), Application, Distribution Channel, and Geography - Global Industry Analysis, Opportunities and Forecast up to 2030
Why Market Study Report?
- Best Price for Reports
- Large Report Database
- Easily Customize Reports
- 24/7 Email & Phone Support
Frequently Asked Questions (FAQ)
Global Glucagon Like Peptide-1 (GLP-1) Agonists Market Size was estimated at USD 7790.46 million in 2022 and is projected to reach USD 18825.17 million by 2028.
Novo Nordisk, AstraZeneca, Eli Lily, GSK, Sanofi, Bristol-Myers Squibb, Amylin
North America,Europe,Asia-Pacific,South America,Middle East & Africa